COPD

1. Evaluating Effective Pharmacotherapy for Post-TB COPD: A Multicentric Real-World Observational Study from India (NAPCON Jaipur 2025) 2. What is the effective pharmacotherapy for Post TB-COPD? An observational multicentric, real world effectiveness study from india (ERS Congress 2025) 3. Prevalence of small airways obstruction (SAO) in post-TB COPD patients: an observational indian multicentric study (ERS Congress 2025) 4. Changes in oscillometry parameters observed in post-TB COPD patients treated with LABA+LAMA and LABA+LAMA+ICS over 3 months: An Indian observational multicentric study (NAPCON Jaipur 2025) 5. Understanding the usage of triple therapy for COPD in india: the SUPREME survey (NAPCON 2023 Hyderabad/Delhi) 6. Prospective, multicentre, phase IV trial evaluating safety and efficacy of glycopyrronium/formoterol/budesonide fixed-dose combination in COPD patients (NAPCON 2023 Hyderabad/Delhi) 7. Efficacy of Budesonide/Glycopyrronium/Formoterol FDC Across Blood Eosinophil Ranges in Indian COPD Patients: Post Hoc Analysis of Phase-4 Clinical Trial (ERS Congress 2024/NAPCON 2023 Hyderabad/Delhi) 8. Benefits of Budesonide/Glycopyrronium/Formoterol on Lung Function, Symptoms and Quality of Life Across Blood Eosinophil Ranges in Indian COPD patients: A post-hoc analysis from a Phase IV Clinical Trial (NAPCON 2023 Hyderabad/Delhi) 9. Perceptions and Usage of Long-Acting Bronchodilators in COPD Among Indian Physicians: PATTERN Study (Amrita Journal of Medicine, April 2025) 10. Survey to Understand Physicians Knowledge, Attitude & Practice Patterns to Vaccinate COPD Patients in India – PREVENT Survey (ERS Congress 2025) 11. Perspectives of physicians on using Erdosteine for managing patients of chronic respiratory diseases with or without excessive sputum production – The ERDO Survey (NAPCON Jaipur 2025)